MK-3475-051
Phase 1/2 Recruiting
370 enrolled
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Phase 1/2 Recruiting
160 enrolled
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Phase 1 Recruiting
572 enrolled
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Phase 2 Recruiting
100 enrolled
QUADvance
Phase 1/2 Recruiting
178 enrolled
A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
Phase 1 Recruiting
84 enrolled
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Phase 2 Recruiting
65 enrolled
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Phase 1/2 Recruiting
69 enrolled
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase 1 Recruiting
50 enrolled
PiNACLE-H2H
Phase 3 Recruiting
400 enrolled
GLOBRYTE
Phase 3 Recruiting
182 enrolled
EPCOREâ„¢FL-2
Phase 3 Recruiting
1,095 enrolled
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
Phase 1/2 Recruiting
180 enrolled
MK-3475-G21
Phase 1/2 Recruiting
20 enrolled
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Phase 1/2 Recruiting
12 enrolled
Study of LYL314 in Aggressive Large B-Cell Lymphoma
Phase 1/2 Recruiting
270 enrolled
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
Phase 2 Recruiting
40 enrolled
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Phase 1/2 Recruiting
32 enrolled
TERZO
Phase 3 Recruiting
124 enrolled
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
Phase 1 Recruiting
80 enrolled
Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
Phase 1/2 Recruiting
41 enrolled
CAMPERR
Recruiting
7,000 enrolled
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
Phase 1 Recruiting
106 enrolled
Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
Phase 1/2 Recruiting
60 enrolled
ON-5001
Phase 1 Recruiting
168 enrolled
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Phase 1/2 Recruiting
70 enrolled
KinLET
Phase 1 Recruiting
20 enrolled
DAHLIA
Phase 1/2 Recruiting
85 enrolled
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Phase 1/2 Recruiting
75 enrolled
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Phase 1/2 Recruiting
120 enrolled
VIPER101
Phase 1 Recruiting
30 enrolled
OPAL
Phase 1/2 Recruiting
144 enrolled
Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies
Phase 1 Recruiting
25 enrolled
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
Phase 1 Recruiting
50 enrolled
Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma
Phase 1/2 Recruiting
99 enrolled
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Phase 1 Recruiting
140 enrolled
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Phase 1 Recruiting
46 enrolled
BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
Phase 1 Recruiting
12 enrolled
A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma(Keyplus-001)
Phase 1 Recruiting
100 enrolled
HOPE
Recruiting
10 enrolled
STARLIGHT-1
Phase 1/2 Recruiting
21 enrolled
A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
Phase 1 Recruiting
56 enrolled
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
Phase NA Recruiting
50 enrolled
PRIMAVERA
Phase 1/2 Recruiting
110 enrolled
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Phase 1/2 Recruiting
275 enrolled
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Phase 1/2 Recruiting
85 enrolled
A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies
Phase 1/2 Recruiting
224 enrolled
DALY II USA/ MB-CART2019.1 for DLBCL
Phase 2 Recruiting
248 enrolled
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
Phase 2 Recruiting
49 enrolled
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Phase 1 Recruiting
72 enrolled